Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF) will present at Sidoti’s Year-End Virtual Investor Conference on December 11, 2025 at 4:00 PM ET. CEO Mark Erlander, PhD will deliver the presentation and host one-on-one meetings during the conference running December 10–11, 2025. Interested parties can register and access the live webcast via the company’s Events section. A webcast replay will be available after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – CRDF
In the Dec 8 session, CRDF gained 10.90%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Investor conference | Neutral | +2.5% | Announcement of Piper Sandler conference presentation and 1x1 investor meetings. |
| Nov 06 | Earnings & update | Positive | -2.7% | Q3 2025 results with positive Phase 2 data and extended cash runway. |
| Nov 04 | Investor conferences | Neutral | +0.9% | Participation in two November 2025 investor conferences with webcasts. |
| Oct 02 | Investor conferences | Neutral | +4.3% | Two October 9, 2025 virtual investor conference appearances announced. |
| Aug 28 | Investor conferences | Neutral | +1.0% | Planned attendance at three major September 2025 healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news flow has been dominated by investor conference participation, which has typically coincided with modest positive price moves, while a fundamentally stronger Q3 update saw a small negative reaction.
Over the last six months, CRDF has frequently announced participation in investor conferences, often accompanied by modest gains of up to about 4% the following day. The notable exception was the 11/06/2025 Q3 2025 earnings and business update, which highlighted positive Phase 2 data and a cash runway into Q1 2027 yet saw the stock down about 2–3%. Today’s Sidoti conference appearance fits the pattern of ongoing investor outreach rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025.
Details of the presentation can be found below.
Presenter: Mark Erlander, PhD (CEO)
Date: 12/11/2025
Time: 4:00 PM ET
Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
